Antivirulence pills to block harmful bacteria’s “sticky” tools (T4P) to fight antibiotic resistance
Official title: Antivirulence Inhibitors of Bacterial Type IV Pili: A Strategy Against Antibiotic Resistance
Funded at Virginia Polytechnic Inst and St Univ · NIH-11379040 · Data updated 2026-11-12
A small study tests new medicines that disarm bacteria instead of killing them, aiming to help people by reducing infections from drug-resistant bacteria.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Polytechnic Inst and St Univ NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project start | June 12, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $225,846 |
| NIH project number | 1R21AI200038-01 |
| Project ID | NIH-11379040 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with infections caused by antibiotic-resistant Gram-negative bacteria where antivirulence strategies could be relevant future options.
✕Less likely to help
Patients with infections not driven by type IV pili or those whose infections do not involve antivirulence strategies may not benefit.
What this research studies
This project focuses on a strategy that makes bacteria less able to cause disease by blocking type IV pili, tiny structures bacteria use to attach and communicate. It uses a short, early-phase design to explore how well these antivirulence compounds work and whether they’re safe. The work is grounded in understanding how these inhibitors affect bacterial behavior rather than simply killing bacteria, with a translational angle toward future human testing. If successful, these antivirulence drugs could complement existing antibiotics and potentially slow resistance.
Why it matters
Potential benefit: If successful, patients could have new therapies that make infections easier to treat and help preserve the effectiveness of current antibiotics.
How similar studies have gone: Antivirulence approaches have shown promise in early studies, but this area remains largely exploratory and/ or preclinical.
Where this research is happening
-
Virginia Polytechnic Inst and St Univ
Blacksburg, United States Active
Researchers
- Principal investigator: Yang, Zhaomin — Virginia Polytechnic Inst and St Univ
- Study coordinator: Yang, Zhaomin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.